Finding new ways to treat glioblastoma by studying cancer cell proteins.
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.
This study is looking at how glioblastoma, a tough type of brain cancer, grows and changes, focusing on a specific protein that helps the cancer cells survive, with the goal of finding new treatment options to help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10880499 on NIH RePORTER |
What this research studies
This research investigates how glioblastoma, a type of brain cancer, grows and evolves by focusing on the epidermal growth factor receptor (EGFR), which is often amplified in these tumors. The team aims to identify specific proteins that glioblastoma cells rely on for survival, even when the tumor is genetically diverse. Using advanced techniques, they will analyze patient-derived models to discover new treatment targets that could lead to more effective therapies for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma, particularly those whose tumors exhibit EGFR amplification.
Not a fit: Patients with glioblastoma who do not have EGFR amplification or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that specifically target glioblastoma cells, potentially improving outcomes for patients.
How similar studies have performed: Other research has shown promise in targeting specific proteins in cancer cells, suggesting that this approach could yield significant advancements in glioblastoma treatment.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Mischel, Paul S — Stanford University
- Study coordinator: Mischel, Paul S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.